- Home
- OMC vs GH Comparison
OMC vs GH Comparison
Compare OMC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMC | GH |
|---|---|---|
| Founded | 1944 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7B | 22.9B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | OMC | GH |
|---|---|---|
| Price | $82.47 | $169.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 26 |
| Target Price | $102.00 | ★ $201.64 |
| AVG Volume (30 Days) | ★ 2.1M | 1.7M |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.88% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 5.77 | N/A |
| Revenue | ★ $17,271,900,000.00 | $982,021,000.00 |
| Revenue This Year | $49.82 | $38.42 |
| Revenue Next Year | N/A | $35.13 |
| P/E Ratio | $61.38 | ★ N/A |
| Revenue Growth | 10.09 | ★ 32.88 |
| 52 Week Low | $66.33 | $68.02 |
| 52 Week High | $89.57 | $191.05 |
Technical Indicators
Market Signals| Indicator | OMC | GH |
|---|---|---|
| Relative Strength Index (RSI) | 64.05 | 51.83 |
| Support Level | $73.53 | $153.88 |
| Resistance Level | $86.80 | $173.94 |
| Average True Range (ATR) | 2.10 | 9.19 |
| MACD | 0.87 | -0.36 |
| Stochastic Oscillator | 69.68 | 39.08 |
Price Performance
Historical ComparisonAbout OMC Omnicom Group Inc.
Omnicom is a holding company that owns several advertising agencies and related firms. It provides traditional and digital advertising services that include creative design, market research, data analytics, ad placement, and public relations. The firm operates globally, providing services in more than 70 countries; it generates more than one half of its revenue in North America and nearly 30% in Europe.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.